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The effect of acute angiotensin II blockade on renal function in
rats with reduced renal mass
KESHWAR BiJ3oouu. and TIMOTHY W. MEYER
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The effect of acute angiotensin II blockade on renal function in rats
with reduced renal mass. The effect of acute Ang II blockade on renal
function in rats with reduced nephron number was assessed in micropunc-
ture studies. The Ang H receptor blocker, losartan, was administered at a
dose of 10 mg iv. at two intervals following five-sixths renal ablation. At
eight weeks following ablation, Ang II blockade (Mg IIX) increased
sodium excretion [UMV, Ang IIX 2.2 0.4 sEq/min; time control (TC)
1.0± 0.3 pEq/min; P < 0.05] but did not reduce mean arterial pressure(AP, Mg HX 142 6 mm Hg; TC 151 6 mm Hg), glomerular
transcapillary pressure (P, Mg fIX 50 1 mm Hg; TC 50 1 mm Hg),
or urine albumin excretion (UbV: Mg IIX 149 18 pg/min; TC 168
20 sg/min). Similarly, at two weeks following ablation, Ang II blockade
increased UNaV (Mg H 2.8 0.4 pEq/min; TC 0.5 0.2 jEqImin; P <
0.05) without reducing AP (Mg IIX 132 6 mm Hg; TC 140 7 mm
Hg), P (Mg fIX 50 3mmHg; TC 48 2mm Hg), or UbV (Ang lix
32 3 jsg/rnin; TC 36 10 g/min). These findings indicate that within
the remnant kidney, Ang II promotes sodium retention but does not have
an acutely reversible effect on glomerular pressure or permselectivity.
Reduction of renal mass leads to hyperfiltration and hypertro-
phy of remnant nephrons. When accomplished by partial renal
infarction in the rat, reduction of renal mass also leads to
increases in systemic and glomerular capillasy pressure [1—3].
Previous studies have suggested that angiotensin II (Ang II)
contributes to these hemodynamic changes and also to the later
development of glomerular injury in the remnant kidney. Ander-
son et a! [1] found that sustained inhibition of Ang II converting
enzyme normalized systemic and glomerular capillary pressure in
rats subjected to renal ablation. Subsequent studies have shown
that Ang II receptor blockade has the same effect as converting
enzyme inhibition in this model [4]. Treatment with an Ang II
receptor blocker for one week has also been shown to reduce
systemic pressure, glomerular pressure, and albumin excretion
rate in renal ablated rats which were maintained without treat-
ment until remnant glomerular injury was established [5]. To-
gether, these findings suggest that endogenous Ang II increases
systemic and glomerular pressure following renal ablation and
promotes albumin filtration in injured remnant glomeruli. The
purpose of the current study was to identify the mechanisms by
which Ang II contributes to these changes. Angiotensin II has
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multiple effects on the kidney. In normal rats, infusion of Ang II
increases sodium reabsorption, increases systemic blood pressure
and glomerular capillary pressure, and reduces the glomerular
ultrafiltration coefficient [6—9]. Each of these effects of exogenous
Ang II can rapidly be reversed by Ang II receptor blockade. Two
previous studies have examined the effect of Ang II blockade or
remnant kidney function [10, 11}. In one study, a peptide Ang II
receptor blocker reduced glomerular capillary pressure and single
nephron GFR while the glomerular ultrafiltration coefficient
remained constant [101. In another study, both a peptide Ang II
receptor blocker and a converting enzyme inhibitor reduced
glomerular capillary pressure and increased the glomerular ultra-
filtration coefficient while single nephron GFR remained stable
[11]. The current study was performed to re-examine the effects of
Ang II blockade on remnant kidney function using a recently
developed non-peptide Ang II receptor blocking agent [12].
Methods
Male Munich Wistar rats with initial weights of 280 to 320 g
were subjected to five-sixths renal ablation by right nephrectomy
and ligation of arterial branches supplying two thirds of the left
kidney. They were maintained on standard chow containing
—24% protein by weight. Micropuncture studies were carried out
in separate groups of rats at eight to twelve weeks and at two
weeks after ablation. At each interval, one group of renal ablated
rats received the non-peptide Ang II receptor antagonist losartan
while a second group of renal ablated rats served as time controls
(N = 6 to 8 rats in each group). Twenty-four-hour urine protein
excretion was measured prior to micropuncture in rats studied at
eight to twelve weeks after ablation so that rats could be divided
into groups with similar glomerular injury. Additional studies
were performed in intact male Munich Wistar rats to confirm that
the dose of losartan used was sufficient to block the effect of Ang
II.
Micropuncture protocol
Rats were anesthetized with mactin (100 mg/kg body wt i.p.)
and placed on a temperature-regulated table. A PE-50 tubing
catheter was inserted in the right femoral artery and used for
subsequent blood sampling and estimation of mean arterial
pressure (AP). AP was continuously monitored with an electronic
transducer connected to a direct writing recorder. After trache-
otomy, PE-50 catheters were inserted in the right and left jugular
veins for infusion of rat plasma, saline, and radiolabled inulin. A
PE-lO catheter was installed into the left ureter for collection of
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urine. Plasma was infused in an amount equal to 1% body weight
over 40 minutes, followed by a reduction of the infusion rate to 0.4
ml/hr for the duration of the study. Saline was infused at 1.2 ml/hr
throughout the study. After 100minutes, tritiated nethoxy-inulin
was added to the saline to achieve an infusion rate of —40 tCi/hr
following a loading dose of —40 gCi. Clearance measurement
were begun after ——120 minutes and carried out over two or three
30 to 40 minute clearance periods. In each period, a 200 j.d arterial
blood sample was obtained for determination of hematocrit and
plasma inulin and protein concentrations. A renal vein blood
sample was obtained with each arterial blood sample for deter-
mination of filtration fraction by renal vein inulin extraction.
In rats studied at eight to twelve weeks after ablation, baseline
measurements of whole kidney function were made during the
first 30-minute clearance period. Time control rats then received
1 ml of normal saline infused i.v. over 10 minutes followed by a
10-minute equilibration period and Ang II blockade rats received
10 mg of losartan in 1 ml of normal saline infused i.v. over 10
minutes followed by a 10-minute equilibration period. Measure-
ments of whole kidney function were then repeated during two
further clearance periods during which micropuncture measure-
ments were performed. Timed (4 mm) samples of tubule fluid
were collected from surface proximal convolutions of three
nephrons for determination of single nephron glomerular filtra-
tion rate (SNGFR). Time averaged hydraulic pressures were
measured in surface glomerular capillaries, proximal tubules, and
efferent arterioles with a continuous recording, servo-null mi-
cropipette transducer system (Model V, Instrumentation for
Physiology and Medicine, San Diego, California, USA). The same
protocol was used in rats studied at two weeks after ablation
except that additional measurements of glomerular capillary and
proximal tubule pressure were made during the baseline clearance
period.
The efficacy of the dose of losartan used was assessed by
measuring the pressor effect of a bolus dose of Ang II, 50 ng i.v.,
at the end of micropuncture studies. Further confirmation of the
efficacy of losartan was obtained by assessing renal function
before and after losartan in normal rats receiving a continuous
infusion of exogenous Ang II. These studies were performed in a
separate group of four intact male Munich Wistar rats weighing
290 to 320 g. Rats were prepared for micropuncture as described
above except that a continuous infusion of Ang II, 150 ng/min was
begun at —60 minutes after anesthesia and continued throughout
the duration of the study. Beginning at —120 minutes after
anesthesia, baseline measurements of whole kidney function and
glomerular and proximal tubule pressure were made during a
30-minute clearance period. Losartan, 10 mg i.v., was then infused
according to the same protocol used in renal ablated rats, and
measurements of whole kidney function and glomerular and
proximal tubule pressure were repeated during an a further
clearance period.
Analytical
The albumin excretion rate was determined by rate nephelom-
etry (Beckman Immunochemistry Analyzer) using anti-rat albu-
min antibody (Cappel Laboratories, Malvern, Pennsylvania,
USA). The protein concentration of arterial plasma (CA) was
determined by refractometry. The radioinulin content of plasma,
urine, and tubule fluid was assessed by liquid-phase scintillation
counting.
Calculation and statistics
Efferent arteriolar protein concentration was calculated from
the relation:
CACE = (1—FF) (1)
Oncotic pressure (-ii) of efferent and afferent arteriolar plasma
was estimated from plasma protein concentration as
= 1.629C + 0.294 C2 (2)
A standard mathematical model was used to derive the glomeru-
lar capillary ultrafiltration coefficient (I(f) [13]. The statistical
significance of differences among values of individual parameters
before and after losartan or normal saline infusion was assessed by
paired t-test and differences between values in losartan treated
and time control rats was assessed by unpaired t-test. Significance
in both cases was defined as P < 0.05. Values are expressed as
means 1 SE throughout.
Results
Studies at eight to twelve weeks
Time control and Ang II blockade rats were matched for body
weight (TC 335 6 g; Ang IIX 331 6 g), weight gain following
ablation (TC 36 5 g; Ang IIX 31 6 g), and 24-hour urine
protein excretion (TC 189 18 mg/day; Ang IIX 214 37
mg/day) prior to study. Mean values for hematocrit, plasma
protein concentration, mean arterial pressure under anesthesia
and the determinants of single nephron GFR are summarized in
Table 1. Values for hematocrit (Hct) and plasma protein concen-
tration (CA) were similar in the two groups. Baseline values for
arterial pressure, GFR, and filtration fraction (FF) were also
similar in the two groups. As expected both groups of remnant
kidney rats exhibited baseline elevation of arterial pressure (TC
148 8 mm Hg; Ang iIX 135 7 mm Hg) and reduction of GFR
(TC 0.72 0.07 ml/min; Ang IIX 0.73 0.10 mI/mm) below levels
observed in intact rats [3]. Infusion of 1.0 ml of normal saline did
not alter values for these parameters in time control rats. Mi-
cropuncture measurements following saline infusion in time con-
trol rats revealed remnant nephron hyperfiltration (SNGFR 124
6 nl/min) with values for single nephron plasma flow (QA428
27 nl/min), glomerular transcapillary hydraulic pressure (AP 50
1 mm Hg) and the glomerular ultrafiltration coefficient (K1 0.091
0.010 nl/(s mm Hg)) similar to those previously observed in
remnant kidney rats at twelve weeks after ablation [4]. Infusion of
losartan had no effect on arterial pressure in Ang II blockade rats
(AP 142 6 mm Hg post-losartan vs. 137 7 mm Hg baseline).
Infusion of losartan did cause a small increase in GFR (0.79
0.10 mI/mm post-losartan vs. 0.73 0.10 baseline) but did not
reduce AP below the value observed in time control rats (50 1
mm Hg post-losartan vs. 50 1 mm Hg time control post-saline).
The absence of a difference in AP in losartan treated and control
rats reflected the absence of differences in glomerular capillary
pressure GC (64 1 mm Hg post-losartan vs. 65 1 mm Hg
post-saline) and proximal tubule pressure T (14 1 mm Hg
post-losartan vs. 15 1 mm Hg post-saline) in the two groups.
Values for urine flow rate, sodium excretion, and albumin excre-
tion are summarized in Table 2. Baseline values for each of these
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Table 1. Glomerular hemodynamic function at eight to twelve weeks
Hct
%
CA
g/dl
AP
mm Hg
GFR
mllmin
FF
%
SNGFR °A
nI/mm
'oc "T L1.1'
iç
mm Hg nl(s' mm Hg)
Time control baseline 45 1 5.9 0.1 148 8 0.72 0.07 0.30 0.01
(N=7) post 44±1 5.7±0.1 151±6 0.74±0.07 030±0.01 124±6 428±27 64±1 14±1 50±1 0.091±0.010
Mg II blockade baseline 45 1 5.8 0.1 135 7 0.73 0.10 0.30 0.02
(N= 7) post 45±1 5.7±0.1 142±6 0.79±0.lOa 0.28±0.02 128±5 431±37 65±1 15±1 50±1 0.078±0.005
Abbreviations are: Hct, hematocrit; CA, afferent arteriolar plasma protein concentration; AP, mean arterial pressure; GFR, glomerular filtration rate;
FF, filtration fraction; SNGFR, single nephron glomerular filtration rate; QA' glomerular plasma flow rate; P0, glomerular capillary pressure; T'
proximal tubule pressure; AP, mean glomerular transcapillary hydraulic pressure difference; Kf, glomerular capillary ultrafiltration coefficient. Data are
mean values sa.
a p < 0.05 post vs. baseline
Table 2. Urine sodium and albumin excretion at eight to twelve weeks
Urine
flow rate
p1/mm
Urinary sodium
excretion
xEq/min
Urinary albumin
excretion
pg/mm
Time control baseline 15 3 1.0 0.3 180 33
(N= 7) post 16±3 1.0 03 168 37
Mg H blockade
(N = 7)
baseline
post
16 2
22
1.0 0.3
2.2 0,4a,b
148 18
149 18
a P C 0.05 post vs. baseline
b P C 0.05 Mg II blockade vs. Time control
parameters were similar in the two groups, with heavy albumin-
uria in each group characteristic of remnant glomerular injury. No
change was observed in urine flow rate, sodium excretion, or
albumin excretion in time control rats. Ang II blockade caused a
significant increase in sodium excretion (2.2 0.4 xEq/min
post-losartan vs. 1.0 0.3 jxEq/min baseline) without altering
albumin excretion (149 18 jig/mm post-losartan vs. 148 18
jig/mm baseline).
Studies at two weeks
Additional studies were performed at two weeks after ablation
to determine if Mg II blockade has effects at this interval which
are no longer present at eight to twelve weeks after ablation. Time
control and Mg II blockade rats were again matched for body
weight (TC 288 7 g; Mg IIX 285 4 g). Rats lost weight over
the two weeks after ablation, but the weight loss was not different
between the two groups (TC 12 5 g; Mg IIX 18 5 g). Mean
values for hematocrit, plasma protein concentration, mean arte-
rial pressure and the determinants of single nephron GFR are
summarized in Table 3. Overall, the results were similar to those
obtained at eight to twelve weeks. Baseline values for arterial
pressure, GFR, and filtration fraction were similar in the two
groups. Both groups of remnant kidney rats exhibited baseline
elevation of arterial pressure (TC 137 8 mm Hg; Mg IIX 136
7 mm Hg) and reduction of GFR (TC 0.70 0.06 ml/min; Mg
lix 0.82 0.03 ml/min) below levels observed in intact rats.
Infusion of 1.0 ml of normal saline did not alter values for these
parameters in time control rats. Micropuncture measurements
following saline infusion in these animals revealed remnant
nephron hyperflltration (SNGFR 77 6 nI/mm) and hyperperfu-
sion (QA 273 34) which were slightly less prominent than at
eight to twelve weeks following ablation. Glomerular transcapil-
lary hydraulic pressure averaged 48 2 mm Hg and K averaged
0.055 0.005 nl/(s mm Hg). Infusion of losartan had no effect on
arterial pressure in Mg II blockade rats (132 6 mm Hg
post-losartan vs. 136 7 mm Hg baseline). As at eight to twelve
weeks, infusion of losartan caused a small increase in GFR (0.91
0.04 mI/mm post-losartan vs. 0.82 0.03 baseline) but did not
reduce iXP. The post-losartan zP value of 50 3 mm Hg in Mg
II blockade rats was not different from the baseline AP value of 50
1 in the same group or from the post-saline AP value of 48
2 mm Hg in time control rats. Constancy of AP following Mg II
blockade with losartan reflected a small, similar increase in GC
(68 3 mm Hg post-losartan vs. 66 1 mm Hg baseline) and T
(18 1 mm Hg post-losartan vs. 15 1 mm Hg baseline). Values
for urine flow rate, sodium excretion, and albumin excretion at
two weeks are summarized in Table 4. Baseline values for
albuminuria showed that glomerular injury was less advanced than
at eight to twelve weeks after ablation. No change was observed in
urine flow rate, sodium excretion, or albumin excretion in time
control rats. Mg II blockade again caused a significant increase in
sodium excretion (2.8 0.5 gEq/min post-losartan vs. 0.3 0.1
jtEq/min baseline, P < 0.05) while slightly increasing albumin
excretion (32 3 gig/mm post-losartan vs. 27 4 gig/mm
baseline).
Losartan dose
The effectiveness of Mg II receptor blockade was first tested by
assessing the pressor response to an intravenous bolus infusion of
Mg II. The pressor response to 50 ng of Mg 11(47 7 mm Hg
in time control rats at eight to twelve weeks and 43 5 mm Hg in
time control rats at two weeks) was ablated by losartan (1 1 mm
Hg in Mg II blockade rats at eight to twelve weeks and 1 1 mm
Hg in Mg II blockade rats at two weeks). To further confirm the
effectiveness of Mg II receptor blockade, experiments were
performed in a separate group of intact rats receiving a continu-
ous infusion of exogenous angiotensin II. Baseline measurements
made during infusion of Mg II revealed high values for AP and
AP comparable to those observed in remnant kidney rats (Table
5). Administration of losartan rapidly reduced AP and AP despite
continued infusion of exogenous Mg II. The reduction of AP,
which averaged 45 mm Hg, was associated with a reduction in
urine flow rate without a significant change in urine sodium or
albumin excretion rate.
Discussion
Renal ablation generally leads to hypertension in the rat. The
magnitude of the increase in blood pressure appears to depend on
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Table 3. Summary of renal cortical microcirculation studies at two weeks
AP
mm Hg
SNGFR QA 'GC 'T AP
Hct
%
CA
gidI
GFR
ml/min
FF
% ni/mm
iç
nl(s' mm Hg)mm Hg
Time control baseline 48 1 5.7 0.1 137 8 0.70 0.06 0.27 0.03 65 1 16 1 49 I
(N=6) post 47±1 5.6±0.1 140±7 0.69±0.06 0.29±0.02 77±6 273±34 65±1 17±1 48±2 0.055±0.005
Ang II blockade baseline 48 1 5.8 0.1 136 7 0.82 0.03 0.27 0.03 66 1 15 1 50 1
(N= 8) post 47±1 5.6±0.1 132±6 0.91 0.25±0.02 86±4 339±34 68±3 18± ia 50±3 0.051
Abbreviations are the same as for Table 1.
a P < 0.05 post vs. baseline
b P < 0.05 Ang IL blockade vs. Time control value for comparable period
Table 4. Urine sodium and albumin excretion at two weeks
Urine
flow rate
ui/mm
Urinary sodium
excretion
p.Eq/min
Urinary albumin
excretion
zg/min
Time control baseline 12 2 0.5 0.1 36 10
(N = 7) post 11 1 0.5 0.1 36 10
Ang LI blockade baseline 9 1 0.3 0.1 27 4
(N = 7) post 22 2a.b 2.8 05a,b 32 3
a P < 0.05 post vs. baseline
b P < 0.05 Ang II blockade vs. Time control
the ablation procedure used and also to vary among individual
animals [2, 14]. When present, systemic hypertension is accompa-
nied by glomerular capillary hypertension and associated with
progressive development of glomerular injury manifested by
proteinuria. The hemodynamic changes can be reversed and the
injury prevented by sustained blockade of Ang II activity [1, 4].
These findings suggest that endogenous Ang II increases systemic
and glomerular pressure and promotes glomerular injury in the
remnant kidney.
The purpose of the current study was to explore the mechanism
by which Ang II increases systemic and glomerular pressure
following renal ablation. Two previous studies have examined this
issue. Rosenberg, Kren and Hostetter [101 found that a peptide
Ang II receptor blocker reduced P0c and SNGFR but did not
change K1 at four weeks following renal ablation in rats main-
tained on a synthetic diet with higher protein and lower sodium
content than standard laboratory chow. Pelayo, Quan and Shanley
[11] found that infusion of a converting enzyme inhibitor and a
peptide Ang II receptor blocker reduced P0 and increased Kf so
as to maintain SNGFR constant at two weeks after ablation in rats
maintained on standard chow. In both these studies, as in the
current study, Ang II blockade did not change systemic blood
pressure, suggesting that systemic hypertension in the renal
ablation model is not caused by direct vasoconstrictor action of
Ang II on the peripheral vasculature. However, in the current
study, we found that Ang II blockade with the non-peptide
receptor antagonist losartan did not reduce GC or zP. No
explanation for the differing effects of Mg II blockade on GC
and K1 in the current study and in the studies of Rosenberg et al
[101 and Pelayo et al [11] is readily apparent. The major effect of
Mg II blockade observed in the current study was to increase
urine sodium excretion. Sodium excretion was not assessed in the
previous studies of the effect of Ang II blockade on remnant
kidney function [10, 11]. The current findings, however, suggest
that a major effect of endogenous Mg II in the remnant kidney is
to promote sodium retention. Other studies suggest that sodium
retention could account for systemic and glomerular hypertension
in the remnant kidney model. Sustained sodium retention is a
known cause of systemic hypertension [15]. Moreover, in the
remnant kidney, autoregulation is impaired, so that increases in
systemic pressure are accompanied by increases in glomerular
pressure [16, 17]. Thus, Mg II could cause remnant glomerular
hypertension indirectly by promoting sodium retention. Such an
effect of Mg II on glomerular pressure would not be reversible by
acute Mg II blockade, in accord with the results of the current
study.
The suggestion that Aug II causes hypertension by promotion
of sodium retention rather than by direct vasoconstriction is
consistent with the finding that ECF volume is increased while
circulating renin activity is low or normal in the renal ablation
model [18—23]. Recent studies have shown further that circulating
angiotensin II levels are normal in renal ablated rats with hyper-
tension [24]. Normal circulating levels of Ang II would not be
expected to cause systemic vasoconstriction but could cause
sodium retention [7]. It should be noted that the sodium retaining
effect of Mg II may be exaggerated in rats subjected to renal
ablation. Because their GFR is reduced these animals must
increase a fractional sodium excretion to approximately four times
normal to excrete the daily sodium load. The "normal" circulating
Mg II activity observed by Kuczera et al [24] following renal
ablation could be inappropriately high in this setting, and losartan
could cause natriuresis by blocking this Ang II activity. Recent
studies suggest that endogenous Aug II tone is sufficient to
promote proximal sodium reabsorption in intact rats [6, 25].
Blockade of Aug II activity with losartan has been shown to
increase sodium excretion in these animals [25, 26]. In the current
study, intact rats whose blood pressure was increased by infusion
of Mg II did not exhibit an increase in sodium excretion when
Mg II activity was blocked and blood pressure was reduced by
losartan. This finding is consistent with previous reports that
changes in systemic pressure offset the direct tubular effect of Mg
II on sodium reabsorption during exogenous Mg II infusion [27].
An alternate possibility is that losartan causes natriuresis by
blocking the activity of Mg II generated within the kidney.
Measurement of intrarenal Aug II levels has not yet been
accomplished in rats subjected to renal ablation. Two studies,
however, have examined renal content of renin and renin message
in this model [22, 28]. Both found an increase in renin and renin
message adjacent to infarct scars and a reduction in renin and
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Table 5. Effect of acute angiotensin II blockade in normal rats receiving intravenous angiotensin II
70±2 14±1 56±2 8±1 0.4±0.1 3±1
51±V 14±1 37±1a 4±r 0.3±0.1 3±1
renin message away from these scars. These findings are consis-
tent with the hypothesis that renin produced in areas adjacent to
infarction causes hypertension and suppresses the production of
renin in the remainder of the kidney. Measurement of renin and
renin message, however, does not provide a direct index of renin
release. Moreover, there is increasing reason to believe that local
Ang II activity at different sites within the kidney does not depend
entirely on renin release from juxtaglomerular cells. Recent
studies suggest that the proximal tubule possesses the elements
required for local generation of Ang II, including renin, angio-
tensinogen, and converting enzyme [29—31]. Levels of Ang II in
proximal tubule fluid have been found to be much higher than
those in the kidney as a whole, suggesting the tubule secretes Ang
II into its lumen [32]. The activity of the proximal tubule renin
angiotensin system could theoretically be altered in the remnant
kidney without a parallel alteration in the circulating renin-
angiotensin system. The recent finding of an increase in glomer-
ular angiotensinase A in renal ablated rats suggests further that
Ang II activity at specific sites in the remnant kidney could be
affected by changes in Ang II degradation rate [33]. Finally, it
should be noted that in one study of renin activity in the remnant
kidney, glomerular renin and renin message were found to be
increased, while total renin in non-infarct areas was reduced [21].
The current results would suggest that renin activity in remnant
glomeruli, though it could contribute to the development of
glomerular injury, is not sufficient to cause a direct, Ang II
mediated increase in glomerular pressure or a reduction in K1.
The current study further suggests that endogenous Ang II does
not have an acutely reversible effect on remnant glomerular
permselectivity. Urinary albumin excretion was unchanged by
losartan at 8 to 12 weeks after ablation. A slight increase in urine
albumin excretion accompanied a similar slight increase in GFR
following losartan administration at two weeks after ablation. In
normal rats, infusion of modest doses of exogenous Aug II
reduces Kf and infusion of large doses of Ang II may cause
proteinuria [8, 34]. The structural changes responsible for these
acute alterations in function have not been identified. Steiner and
Blantz [9] have shown, however, that the reduction in K caused by
exogenous Ang II in normal rats can rapidly be reversed by Aug
II blockade. This finding was confirmed in experiments performed
to establish the adequacy of the losartan dose used in the current
study. In remnant kidney rats, losartan did not cause an acute
increase in K1 or an acute reduction in albuminuria. Previous
studies in the remnant kidney rat have shown that sustained Aug
II blockade increases K1 and largely prevents development of
albuminuria. These studies have shown further that after albu-
minuria is established, one week of Aug II blockade increases K
and reduces the albumin excretion rate by restoring glomerular
size-selectivity toward normal [4, 5]. Together, these results
suggest that endogenous Aug II contributes to the progressive
development of size-selectivity defects in remnant glomeruli but
that the rate at which macromolecules escape through such
defects is not acutely dependent on Ang II activity. These results
are consistent with recent studies in human renal disease, which
have shown that Aug II converting enzyme reduces protein
excretion rate only over a period of days, and that the reduction
of protein excretion rate achieved by converting enzyme inhibition
is not reversed by acute administration of Aug II [35, 36].
While the current data are consistent with the hypothesis that
the major effect of Aug II in the remnant kidney is to promote
sodium retention, it should be acknowledged that other interpre-
tations of these data are possible. First, it is always difficult to
establish that the activity of an endogenous hormone has been
completely blocked. The dose of losartan used in the current study
was sufficient to reverse the increase in AP and the reduction in K1
caused by exogenous Aug II. The possibility that endogenous Aug
II reaches a different population of receptors and has actions
which are not blocked by losartan, however, cannot be excluded.
Moreover, sustained Aug II activity may cause changes other than
sodium retention which are not acutely reversible by Aug II
receptor blockade. Changes in vascular structure caused by the
combination of increased blood pressure and Aug II activity have
been blamed for the occasional persistence of hypertension
following removal of the clipped kidney in rats with two-kidney
one-clip Goldblatt hypertension. Aug II may also simulate pro-
duction of other vasoactive hormones, including endothelin,
which has been found to have increased activity in the remnant
kidney [37]. The possibility that Ang II stimulates endothelin
production is of particular interest since the long-acting vasocon-
strictor effects of endothelin might not be acutely reversed by Aug
II receptor blockade.
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